Inhibition of staphylothrombin by dabigatran reduces Staphylococcus aureus virulence. 2011

T Vanassche, and J Verhaegen, and W E Peetermans, and J VAN Ryn, and A Cheng, and O Schneewind, and M F Hoylaerts, and P Verhamme
Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium. thomas.vanassche@med.kuleuven.be

BACKGROUND Staphylocoagulase and von Willebrand binding protein (VWbp) bind to prothrombin to form the staphylothrombin complex that converts fibrinogen into fibrin. OBJECTIVE To study the role of staphylothrombin and its inhibition by dabigatran on Staphylococcus aureus virulence. METHODS We studied the effect of staphylothrombin inhibition on bacterial attachment to polystyrene surfaces, leukocyte activation and bactericidal activity for S. aureus ATCC 25923, S. aureus Newman, and staphylocoagulase- and VWbp-negative S. aureus Newman mutants in the presence or absence of prothrombin and fibrinogen. We measured the abscess size after subcutaneous (s.c.) injection of S. aureus ATCC 25923 and S. aureus Newman, as well as an S. aureus Newman mutant strain lacking staphylocoagulase and VWbp, in mice treated with either dabigatran or placebo. RESULTS Staphylothrombin-mediated fibrin increased the association of S. aureus to polystyrene surfaces and reduced the bactericidal activity of leukocytes. The absence or inhibition of staphylothrombin decreased the bacterial association, enhanced leukocyte activation and reduced bacterial survival in vitro. Abscess size was smaller in mice treated with dabigatran or infected with a coagulase-negative mutant. CONCLUSIONS Inhibition or the absence of staphylothrombin reduced S. aureus virulence in in vitro and in vivo models.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D000069604 Dabigatran A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation. BIBR 1048,Dabigatran Etexilate,Dabigatran Etexilate Mesylate,N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-beta-alanine,Pradaxa,Etexilate Mesylate, Dabigatran,Etexilate, Dabigatran,Mesylate, Dabigatran Etexilate
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001422 Bacterial Adhesion Physicochemical property of fimbriated (FIMBRIAE, BACTERIAL) and non-fimbriated bacteria of attaching to cells, tissue, and nonbiological surfaces. It is a factor in bacterial colonization and pathogenicity. Adhesion, Bacterial,Adhesions, Bacterial,Bacterial Adhesions
D001562 Benzimidazoles Compounds with a BENZENE fused to IMIDAZOLES.
D013211 Staphylococcus aureus Potentially pathogenic bacteria found in nasal membranes, skin, hair follicles, and perineum of warm-blooded animals. They may cause a wide range of infections and intoxications.
D013917 Thrombin An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN. Thrombase,Thrombin JMI,Thrombin-JMI,Thrombinar,Thrombostat,alpha-Thrombin,beta,gamma-Thrombin,beta-Thrombin,gamma-Thrombin,JMI, Thrombin

Related Publications

T Vanassche, and J Verhaegen, and W E Peetermans, and J VAN Ryn, and A Cheng, and O Schneewind, and M F Hoylaerts, and P Verhamme
February 2019, Microbial pathogenesis,
T Vanassche, and J Verhaegen, and W E Peetermans, and J VAN Ryn, and A Cheng, and O Schneewind, and M F Hoylaerts, and P Verhamme
September 2015, Nature communications,
T Vanassche, and J Verhaegen, and W E Peetermans, and J VAN Ryn, and A Cheng, and O Schneewind, and M F Hoylaerts, and P Verhamme
November 2016, FEMS microbiology letters,
T Vanassche, and J Verhaegen, and W E Peetermans, and J VAN Ryn, and A Cheng, and O Schneewind, and M F Hoylaerts, and P Verhamme
January 1953, Archives. Middlesex Hospital,
T Vanassche, and J Verhaegen, and W E Peetermans, and J VAN Ryn, and A Cheng, and O Schneewind, and M F Hoylaerts, and P Verhamme
September 2010, Applied and environmental microbiology,
T Vanassche, and J Verhaegen, and W E Peetermans, and J VAN Ryn, and A Cheng, and O Schneewind, and M F Hoylaerts, and P Verhamme
May 2011, Biological chemistry,
T Vanassche, and J Verhaegen, and W E Peetermans, and J VAN Ryn, and A Cheng, and O Schneewind, and M F Hoylaerts, and P Verhamme
May 1999, FEBS letters,
T Vanassche, and J Verhaegen, and W E Peetermans, and J VAN Ryn, and A Cheng, and O Schneewind, and M F Hoylaerts, and P Verhamme
January 2016, PloS one,
T Vanassche, and J Verhaegen, and W E Peetermans, and J VAN Ryn, and A Cheng, and O Schneewind, and M F Hoylaerts, and P Verhamme
April 2019, Microbiology spectrum,
T Vanassche, and J Verhaegen, and W E Peetermans, and J VAN Ryn, and A Cheng, and O Schneewind, and M F Hoylaerts, and P Verhamme
December 2023, Microbiology spectrum,
Copied contents to your clipboard!